RxDoctor Payments Data

Charles Olsen, NP

Psychiatric/Mental Health · Crossville, TNNPI 1053795518

Payments from drug & device makers

$1,695in general payments, 2019–2025

Across 75 payments — averaging $22.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$418
  • Johnson & Johnson$252
  • Axsome Therapeutics, Inc.$212
  • Alkermes, Inc.$151
  • E.r. Squibb & Sons, L.L.C.$148
  • Sunovion Pharmaceuticals Inc.$135
  • plus $381 from 6 others

What the payments were for

  • Food & beverage$1,64897%
  • Education$473%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,695 in reported general payments places this provider in the 65th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$45,963
Medicare patients
110
Services billed
1,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl17$20,206
TrintellixVortioxetine Hydrobromide12$12,102
Desvenlafaxine Succinate ErDesvenlafaxine Succinate100$9,075
VyvanseLisdexamfetamine Dimesylate19$7,001
FetzimaLevomilnacipran Hcl12$5,629
Bupropion XlBupropion Hcl139$4,388
Aripiprazole57$3,782
Buspirone Hcl117$3,198
Duloxetine Hcl104$2,790
Venlafaxine Hcl ErVenlafaxine Hcl104$2,420
Quetiapine Fumarate164$2,260
Mirtazapine94$2,120
Lurasidone Hcl13$1,900
Atomoxetine Hcl14$1,774
Vilazodone Hcl17$1,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$418$25,83529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Crossville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →